Dicot Pharma AB Logo

Dicot Pharma AB

Developing next-gen potency drugs for erectile dysfunction and premature ejaculation.

DICOTBT | SPGR

Overview

Corporate Details

ISIN(s):
SE0011178458 (+1 more)
LEI:
549300GX132RSE4OV407
Country:
Sweden
Address:
St Olofsgatan 11A, 753 21 Uppsala
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Dicot Pharma AB is a pharmaceutical company focused on developing the next generation of potency drugs. Its lead drug candidate, LIB-01, is in development for the treatment of erectile dysfunction and premature ejaculation. The company's objective is for LIB-01 to offer significant advantages over existing therapies, including a longer duration of effect, fewer side effects, and efficacy for a broader patient population. Dicot Pharma aims to establish LIB-01 as a first-choice treatment globally, addressing the needs of the over 500 million men worldwide affected by these conditions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dicot Pharma AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Dicot Pharma AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-30 Per-Anders Hedin Other Other 5,000,000 110,000.00 SEK
2024-08-30 Johan Granath Other Other 1,000,000 22,000.00 SEK
2024-08-28 Erik Johansson Klang Other Buy 60,000 611,400.00 SEK
2024-08-27 Hanna Bodbacka Other Buy 15,000 40,800.00 SEK
2024-08-27 Børge Granli Other Buy 500 14,000.00 SEK
2024-08-27 Carl Johan Magnus Sundell Other Buy 70,000 190,400.00 SEK
2024-08-26 Victor- Persson Other Sell 2,500,000 1,648.53 SEK
2024-08-26 Daniel Nilsson Other Buy 250,000 10,000.00 SEK
2024-08-26 Kent-Ove Stenberg Other Buy 500,000 20,000.00 SEK
2024-08-26 Sten Hedbäck Other Other 200,000 574,000.00 SEK

Peer Companies

Company Country Ticker View
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN
Aladdin Healthcare Technologies SE Logo
Develops AI for drug discovery and diagnostics targeting age-related diseases.
Germany NMI
Alten Logo
Global engineering and IT consulting for digital transformation in industry and telecom sectors.
France ATE
Amoéba Logo
Develops amoeba-based natural fungicides for agriculture and active ingredients for cosmetics.
France ALMIB
APTAMER GROUP PLC Logo
Develops custom aptamer-based binders as antibody alternatives for life science applications.
United Kingdom APTA
Aran Research & Development (1982) Ltd. Logo
End-to-end product & machine development for plastics, medical, and industrial markets.
Israel ARAN
ARIX BIOSCIENCE PLC Logo United Kingdom ARIX
Asarina Pharma AB Logo
Developed Sepranolone for neurological disorders like Tourette's, OCD, and menstrual migraine.
Sweden ASAP

Talk to a Data Expert

Have a question? We'll get back to you promptly.